Prime Medicine Q3 Results: EPS beats estimate, sales up 244% YoY

Prime Medicine (PRME) reported Q3 EPS of $(0.22), beating estimates by 12%, and sales of $4.213M, up 244% YoY. The FDA cleared its PM647 drug for clinical trials, but shares fell 6.19%. The company aims to treat Alpha-1 Antitrypsin Deficiency with PM647, expecting initial trial data in 2027.

Original reporting
Published Nov 12, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prime Medicine Q3 Results: EPS beats estimate, sales up 244% YoY — source image
Decision brief

The 30-second read

$PRMEBearishMed
01

Why it matters

The combination of earnings beat and IND clearance generated a mixed market reaction, with the stock sliding as investors remain cautious about cash burn and future trial outcomes.

02

Market read

Primary biotech news with direct impact on PRME; limited spillover to broader market.

03

What to watch

Cash runway and upcoming trial costs may constrain near‑term upside despite the regulatory win.

Relevance 8/10Novelty 8/10Timing: today

Background

Prime Medicine is a biotech focused on prime editing therapies for liver diseases. The Q3 report showed a sharp revenue rise but still a loss per share.

Company-level read

Ticker impact

$PRMEBearishHigh confidence
Context

Prime Medicine reported Q3 earnings beat and FDA IND clearance for PM647, but shares fell 6.2% on the news.

Expected impact

likely continued modest downside as investors weigh the limited revenue against high cash burn

Evidence & confidence

The earnings beat was modest and the IND clearance does not immediately translate to revenue; the stock already slipped, suggesting short‑term pressure.

Market effects

Highlights ongoing interest in liver‑directed gene editing, may boost sentiment for similar biotech peers.

Limited to US biotech sector; no broader regional effect.

Modest; FDA clearance is US‑specific and does not immediately affect global markets.

Counterpoint

The clearance could be a catalyst for a longer‑term rally if Phase 1/2 data prove compelling.

Key entities

  • Prime Medicine Inc

    NASDAQ‑listed biotech developing prime editing therapies.

  • FDA

    U.S. Food and Drug Administration, granted IND clearance for PM647.

Related articles

$PRMEHighAI 8/10

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine (Nasdaq: PRME) closed a public offering of 41.07 million shares at $3.50 per share, raising $143.7 million. The offering included additional shares due to underwriters' full option exercise. Jefferies, TD Cowen, and Goldman Sachs led the offering. Proceeds will support the biotech company's gene editing therapies.

$PRMEMedAI 8/10

Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine, Inc. (PRME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates -- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial

$PRMEMedAI 8/10

Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine reported Q3 2026 results, including dosing the first patient in a Phase 1/2 trial for PM577a in Wilson disease and FDA clearance for PM647 in Alpha-1 Antitrypsin Deficiency. The company plans a BLA submission for PM359 in early 2027 and raised $143.7 million in a public offering, with a cash runway through 2027. According to the CEO, these developments highlight the versatility of their platform and potential for expansion.

$PRMEMedAI 8/10

Prime Medicine Prices $125 Million Stock Offering at $3.50 Per Share

Prime Medicine (PRME) plans to raise $125 million via a public offering of 35.7 million shares at $3.50 each, with an option for $134.7 million if additional shares are purchased. Proceeds will fund disease programs and R&D. The offering is underwritten by Jefferies, TD Securities, and Goldman Sachs, and is expected to close around Nov 12, 2026, according to the company.